N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy - Full Text View

Purpose

The study is designed to test if the combination of two potent antioxidant nutritional supplements, N-acetylcysteine and the milk thistle extract silibin, is capable of correcting the shedding of urine protein, the oxidative stress, and the inflammation in patients with type 2 diabetes mellitus and diabetic kidney disease.

Condition	Intervention	Phase
Diabetic Nephropathies Proteinuria Oxidative Stress	Dietary Supplement: N-acetylcysteine Dietary Supplement: silibin Dietary Supplement: high-dose silibin Dietary Supplement: N-acetylcysteine placebo Dietary Supplement: silibin placebo	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy.

Resource links provided by NLM:

MedlinePlus related topics: Diabetic Kidney Problems Kidney Diseases

Drug Information available for: Acetylcysteine

U.S. FDA Resources

Further study details as provided by The University of Texas Health Science Center at San Antonio:

Primary Outcome Measures:

Urinary Albumin excretion [ Time Frame: 3-month ]

Secondary Outcome Measures:

urinary alpha-1 microglobulin excretion [ Time Frame: 3-month ]
urinary C-C-chemokines excretion [ Time Frame: 3-month ]
peripheral blood monocyte glutathione content [ Time Frame: 3-month ]
tolerance and safety [ Time Frame: 3-month ]


Enrollment:	114
Study Start Date:	October 2009
Study Completion Date:	April 2016
Primary Completion Date:	April 2016 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Placebo Comparator: Placebo N-acetylcysteine placebo + silibin placebo	Dietary Supplement: N-acetylcysteine placebo excipient orally twice daily for three months Other Name: NAC placebo Dietary Supplement: silibin placebo excipient orally twice daily for three months Other Name: silibin-phosphatidylcholine placebo, Siliphos placebo
Experimental: N-acetylcysteine N-acetylcysteine active + silibin placebo	Dietary Supplement: N-acetylcysteine 600 mg orally twice daily for three months Other Name: NAC Dietary Supplement: silibin placebo excipient orally twice daily for three months Other Name: silibin-phosphatidylcholine placebo, Siliphos placebo
Experimental: silibin N-acetylcysteine placebo + silibin active	Dietary Supplement: silibin 480 mg orally twice daily for three months Other Name: silibin-phosphatidylcholine, Siliphos Dietary Supplement: N-acetylcysteine placebo excipient orally twice daily for three months Other Name: NAC placebo Dietary Supplement: silibin placebo excipient orally twice daily for three months Other Name: silibin-phosphatidylcholine placebo, Siliphos placebo
Experimental: N-acetycysteine + silibin N-acetylcysteine active + silibin active	Dietary Supplement: N-acetylcysteine 600 mg orally twice daily for three months Other Name: NAC Dietary Supplement: silibin 480 mg orally twice daily for three months Other Name: silibin-phosphatidylcholine, Siliphos Dietary Supplement: silibin placebo excipient orally twice daily for three months Other Name: silibin-phosphatidylcholine placebo, Siliphos placebo
Experimental: N-acetylcysteine + high-dose silibin N-acetylcysteine active + high-dose silibin active	Dietary Supplement: N-acetylcysteine 600 mg orally twice daily for three months Other Name: NAC Dietary Supplement: high-dose silibin 960 mg orally twice daily for three months Other Name: silibin-phosphatidylcholine, Siliphos

Detailed Description:

Oxidative stress and GSH imbalance are major contributors to the pathogenesis of diabetic nephropathy. Current options for the treatment of oxidative stress in diabetic nephropathy are limited and only partially effective, thus interest in the development of new strategies is high.

The study intends to test the hypothesis that combined oral supplementation of the antioxidants N-acetylcysteine (NAC) and milk thistle flavonolignan silibin (as silibin-phosphatidylcholine) will reduce proteinuria and urinary and systemic manifestations of oxidative stress and inflammation, which are characteristically observed in patients with type 2 diabetes mellitus and related nephropathy. We expect these effects to be achieved with minimal or no side effects, and with good patient tolerance.

The trial is designed as a two-center, double-blind, placebo-controlled, randomized, modified-factorial dose-ranging design, five-arm pilot study in patients with Type 2 diabetes mellitus and advanced diabetic nephropathy with proteinuria.

Intervention consists of three-month oral administration of NAC, silibin, and/or respective placebos for three months. Subjects are randomized to the following five intervention arms: (A) placebo; (B) NAC; (C) silibin; (D) NAC + silibin; and (E) NAC + double-dose silibin.

The primary outcome measure is urinary excretion of albumin, a marker of glomerular injury. Secondary outcome measures are alpha-1 microglobulin, a marker of tubular injury, and urinary excretion of inflammatory cytokines and C-C chemokines, i.e. markers of renal inflammation. In addition, peripheral blood monocytes from the same patients are analyzed for glutathione (GSH) content and activity of GSH metabolizing enzymes. All outcome measures are monitored in relation to both treatment allocation and prevalent blood and urine levels of the active treatment. Safety and tolerability of this combination treatment are monitored throughout the trial.

Eligibility


Ages Eligible for Study:	18 Years to 70 Years (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Males or females, age 18-70 years old.
Type 2 diabetes mellitus
Diabetic nephropathy, as defined by:
- estimated GFR between 60 and 15 ml/min,
- presence of proteinuria.
Current medical treatment with low dose aspirin
Treatment of hypertension with (but not limited to) one diuretic, one beta- blocker and one medication from the classes ARBs or ACE inhibitors.
Treatment of hyperglycemia with (but not limited to) glipizide and the medication class insulin.
Treatment of hypercholesterolemia with (but not limited to) one medication from the class statins.

Exclusion Criteria:

Type 1 diabetes mellitus.
Glycosylated hemoglobin (HbA1C) > 10%
>20% variation in estimated GFR, during last 6 months
SBP >170 mmHg or DBP >100 mmHg on medications
Other secondary forms of hypertension (endocrine, renovascular)
History of intolerance to:
- Both ACE-I and ARBs;
- The investigational supplements;
- Iodinated radiologic contrast material.
Known non diabetic renal disease, or history of solid organ transplantation.
Hepatitis virus or Human Immunodeficiency virus infections
Use of one of the following medications within 2 months prior to enrollment in the study:
- Metformin.
- Thiazolidinediones (pioglitazone or rosiglitazone);
- Prescription-grade vitamin E, vitamin C, systemic steroids, and/or non-steroidal anti-inflammatory agents;
- Over-the-counter vitamin E, vitamin C, and/or non-steroidal anti-inflammatory agents.
- Over-the-counter antioxidants supplements including: Lipoic acid, Coenzyme Q10, N-acetyl-cysteine (NAC), Glutathione (GSH), Chromium, Fish-oil extracts (omega-3 fatty acids), Soy extracts (isoflavones), Milk thistle extract (silymarin), Green-tea preparations, Pomegranate extracts, Grape extracts, and Prickly pear extract.
Active coronary artery disease or cerebral vascular disease within 3 months prior to signing the informed consent.
Hepatic dysfunction as defined by abnormal total bilirubin or liver enzymes (ALT, AST) >2 times upper limit of normal range.
Active malignancy.
History of drug or alcohol dependency.
Psychiatric or neurological condition, preventing aware consent to the study and/or adherence to the study protocol
Unwillingness to practice birth control throughout the study.
Participation to another clinical study within 1 month prior to signing the informed consent form.
Planned move to outside the study area, surgery or radiographic studies utilizing iodine-based contrast material within the next one year

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00915200

Locations


United States, Texas
University of Texas Hlth Sci Ctr San Ant
San Antonio, Texas, United States, 78229

Sponsors and Collaborators

The University of Texas Health Science Center at San Antonio

National Center for Complementary and Integrative Health (NCCIH)

VA Office of Research and Development

Investigators


Principal Investigator:	Paolo Fanti, M.D.	University of Texas

More Information


Responsible Party:	The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov Identifier:	NCT00915200 History of Changes
Other Study ID Numbers:	NIH 1R21AT004490 1I01CX000264-01A2 ( US NIH Grant/Contract Award Number ) R21AT004490 ( US NIH Grant/Contract Award Number )
Study First Received:	June 2, 2009
Last Updated:	June 23, 2016

Keywords provided by The University of Texas Health Science Center at San Antonio:


Diabetic Nephropathies Proteinuria Renal Insufficiency, Chronic Monocytes Oxidative stress Inflammation	Antioxidants Glutathione Silymarin Acetylcysteine Dietary Supplements Complementary Therapies

Additional relevant MeSH terms:


Kidney Diseases Diabetic Nephropathies Proteinuria Urologic Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Urination Disorders Urological Manifestations Signs and Symptoms Silybin Silymarin	Acetylcysteine N-monoacetylcystine Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Antiviral Agents Anti-Infective Agents Expectorants Respiratory System Agents Free Radical Scavengers Antidotes

ClinicalTrials.gov processed this record on June 23, 2017